Dina Ramadane
Stock Analyst at Bank of America Securities
(2.89)
# 2,720
Out of 4,478 analysts
19
Total ratings
66.7%
Success rate
10.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dina Ramadane
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Downgraded: Sell | $12 → $11 | $16.05 | -31.46% | 7 | Jun 29, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $66 → $65 | $40.13 | +61.97% | 6 | May 22, 2026 | |
| PROK ProKidney | Reiterated: Sell | $1 | $1.99 | -49.75% | 2 | May 18, 2026 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $22 | $17.97 | +22.43% | 2 | May 7, 2026 | |
| CPRX Catalyst Pharmaceuticals | Reiterated: Buy | $35 | $31.50 | +11.11% | 1 | Apr 27, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $32 | $38.60 | -17.10% | 1 | Feb 6, 2026 |
Biohaven
Jun 29, 2026
Downgraded: Sell
Price Target: $12 → $11
Current: $16.05
Upside: -31.46%
Vera Therapeutics
May 22, 2026
Reiterated: Buy
Price Target: $66 → $65
Current: $40.13
Upside: +61.97%
ProKidney
May 18, 2026
Reiterated: Sell
Price Target: $1
Current: $1.99
Upside: -49.75%
Amylyx Pharmaceuticals
May 7, 2026
Reiterated: Buy
Price Target: $22
Current: $17.97
Upside: +22.43%
Catalyst Pharmaceuticals
Apr 27, 2026
Reiterated: Buy
Price Target: $35
Current: $31.50
Upside: +11.11%
Immunovant
Feb 6, 2026
Reiterated: Buy
Price Target: $32
Current: $38.60
Upside: -17.10%